id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-0770-0006,FDA,FDA-2020-D-0770,"Best Practices in Developing 
Proprietary Names for Human 
Nonprescription Drug Products; Draft 
Guidance for Industry; Availability; 
Reopening of the Comment Period",Notice,Notice of Availability,2021-03-16T04:00:00Z,2021,3,2021-03-16T04:00:00Z,2021-06-15T03:59:59Z,2021-06-15T01:00:39Z,2021-05323,0,0,0900006484a6c6e5
FDA-2020-D-0770-0005,FDA,FDA-2020-D-0770,Supplement from Consumer Healthcare Products Association (CHPA),Other,Supplement (SUP),2021-02-26T05:00:00Z,2021,2,2021-02-26T05:00:00Z,,2021-02-26T22:18:33Z,,0,0,0900006484a21351
FDA-2020-D-0770-0003,FDA,FDA-2020-D-0770,Request for Extension from Consumer Healthcare Products Association (CHPA),Other,Request for Extension,2021-01-11T05:00:00Z,2021,1,2021-01-11T05:00:00Z,,2021-01-11T20:28:54Z,,0,0,09000064849ea5ba